Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01202266 · ClinicalTrials.gov registry record · Phase 1
A Multiple Dose Study Of PF-05161704 In Healthy Volunteers
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01202266 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 32 participants.
The verdict
NCT01202266, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of multiple escalating oral doses of PF-05161704 in healthy volunteers
Interventions
- DRUG PF-05161704 or Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2010-08 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01202266
The ClinicalTrials.gov registry entry for NCT01202266 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-05161704 or Placebo is the first listed.
NCT01202266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01202266 about?
NCT01202266 is a clinical study titled "A Multiple Dose Study Of PF-05161704 In Healthy Volunteers". The primary purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of multiple escalating oral doses of PF-05161704 in healthy volunteers
What is the current status of trial NCT01202266?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2010-08. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01202266?
The interventions under investigation include: PF-05161704 or Placebo (DRUG).
Who is sponsoring clinical trial NCT01202266?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.